{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-012921","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.254323+00:00","generated_at":"2026-05-26T22:36:55.231649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Applied DNA exits DNA tagging business, cuts 20% headcount; Q1 revenue $1.2M (+34% YoY), net loss $2.7M","bullets":["Revenue $1.2M (+34% YoY); operating loss $3.0M vs $3.8M; net loss $2.7M vs $1.1M.","Exiting DNA Tagging segment; workforce reduction 20% (13% annual payroll cut); ~$300k severance in Q2 FY25.","GMP Site 1 completed Jan 31, 2025, ISO 7/5 certified; projected annual revenue $10M-$30M at full capacity.","Cash $9.3M as of Dec 31, 2024, includes $5.7M net from October registered direct offering.","First-in-human clinical validation of Linea DNA in CAR-T therapy under Czech regulatory approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-012921","json":"https://secwatch.observer/filing/0001104659-25-012921.json","markdown":"https://secwatch.observer/filing/0001104659-25-012921.md","text":"https://secwatch.observer/filing/0001104659-25-012921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465925012921/0001104659-25-012921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465925012921/tm256524d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:36:55.231649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}